Glucose

Generic Name: Glucose

Brand Names: Bss Ophthalmic Solution, Citrasate, Clinimix 2.75/5, Clinimix E 2.75/5, Dextroject, Dianeal, H.E.L.P.bicel, Hemosate Ultra, Lactate 1-2-3, Leukotrap, Naturalyte, Nauzene, Normosol-R, Nxstage Pureflow, Olimel, Periolimel, Physioneal 40, Sag-M, Sclerodex, Selectbag One

Drug Type: Small Molecule

Unique Ingredient Identifier: IY9XDZ35W2

Background: Glucose is a simple sugar (monosaccharide) generated during phosynthesis involving water, carbon and sunlight in plants. It is produced in humans via hepatic gluconeogenesis and breakdown of polymeric glucose forms (glycogenolysis). It circulates in human circulation as blood glucose and acts as an essential energy source for many organisms through aerobic or anaerobic respiration and fermentation. It is primarily stored as starch in plants and glycogen in animals to be used in various metabolic processes in the cellular level. Its aldohexose stereoisomer, dextrose or D-glucose, is the most commonly occurring isomer of glucose in nature. L-glucose is a synthesized enantiomer that is used as a low-calorie sweetener and laxative. The unspecified form of glucose is commonly supplied as an injection for nutritional supplementation or metabolic disorders where glucose levels are improperly regulated. Glucose is listed on the World Health Organization's List of Essential Medicines.

Indication: Glucose pharmaceutical formulations (oral tablets, injections) are indicated for caloric supply and carbohydrate supplementation in case of nutrient deprivation. It is also used in metabolic disorders such as hypoglycemia.

Associated Conditions: Arrhythmia, Caloric Deficit, Edema of the cerebrum, Hypoglycemia, Metabolic Alkalosis

Associated Therapies: Blood Specimen Collection, Electrolyte replacement, Nutritional supplementation, Parenteral Nutrition, Parenteral rehydration therapy, Plasmapheresis, Positive cardiac inotropic effect, Total parenteral nutrition therapy, Urine alkalinization therapy, Fluid and electrolyte maintenance therapy

Clinical Trials

Changes in Cytokine Levels After Dextrose Injection in Stage IV Knee Osteoarthritis

Not Applicable

Completed

Conditions: Osteoarthritis, Knee

Interventions: Drug: Aspiration 0
Drug: Dextrose 0
Drug: Aspiration 1
Drug: Dextrose 1

First Posted Date: 2018-01-17

Last Posted Date: 2022-08-11

Lead Sponsor: Fisiatria y Traumatología

Target Recruit Count: 20

Registration Number: NCT03400631

Locations: 🇦🇷
Gaston Topol, M.D.. Private Office, Rosario, Santa Fe, Argentina

A Study to Evaluate a Potassium Normalization Treatment Regimen Including Sodium Zirconium Cyclosilicate (ZS) Among Patients With S-K ≥5.8

Phase 2

Completed

Conditions: Hyperkalemia

Interventions: Drug: Sodium Zirconium Cyclosilicate(ZS)
Drug: Placebo
Drug: Insulin
Drug: Glucose

First Posted Date: 2017-11-09

Last Posted Date: 2020-01-28

Lead Sponsor: AstraZeneca

Target Recruit Count: 70

Registration Number: NCT03337477

Locations: 🇷🇺
Research Site, Yekaterinburg, Russian Federation

Exceptional Experiences (EE), Salience & Dopaminergic Neurotransmission

Early Phase 1

Completed

Conditions: Healthy
Schizotypal Personality

Interventions: Drug: 200 mg levodopa/50 mg benserazide
Drug: Dextrose

First Posted Date: 2017-11-06

Last Posted Date: 2017-11-06

Lead Sponsor: University of Zurich

Target Recruit Count: 65

Registration Number: NCT03333369

Locations: 🇨🇭
Collegium Helveticum, ETH & Universität Zürich, Zürich, Switzerland

First-in-human Study in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: CORT118335, 25 mg
Drug: Placebo oral capsule
Drug: CORT118335, 75mg
Drug: CORT118335, 225mg
Drug: CORT118335, 675mg
Drug: CORT118335, 600mg
Drug: Prednisone Oral Tablet
Drug: CORT118335, 375mg
Drug: CORT118335, 100mg
Drug: Placebo oral suspension
Drug: CORT118335, 300mg
Drug: CORT118335, 900mg
Drug: CORT118335, 1500mg
Drug: CORT118335, 150mg
Drug: CORT118335, dose to be determined
Drug: Glucose
Drug: CORT118335, 630mg

First Posted Date: 2017-10-20

Last Posted Date: 2019-05-24

Lead Sponsor: Corcept Therapeutics

Target Recruit Count: 143

Registration Number: NCT03315338

Locations: 🇬🇧
Quotient Clinical, Nottingham, Nottinghamshire, United Kingdom

Intrapartum Glucose and Insulin Compared to Glucose Alone in Diabetic Women

Not Applicable

Recruiting

Conditions: Obstetric Labor
Pregnancy in Diabetics

Interventions: Drug: glucose solution and Insulin
Drug: glucose solution only

First Posted Date: 2017-09-06

Last Posted Date: 2023-10-11

Lead Sponsor: HaEmek Medical Center, Israel

Target Recruit Count: 200

Registration Number: NCT03273881

Locations: 🇮🇱
HaEmek medical center, Afula, Israel

Liver Glycogen and Hypoglycemia in Humans

Phase 1

Active, not recruiting

Conditions: Hypoglycemia; Iatrogenic

Interventions: Drug: Saline
Drug: Low Fructose
Drug: Somatostatin
Drug: Insulin
Drug: Glucagon
Drug: High Fructose
Drug: Dextrose solution

First Posted Date: 2017-08-07

Last Posted Date: 2024-02-28

Lead Sponsor: Jason Winnick

Target Recruit Count: 40

Registration Number: NCT03241706

Locations: 🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States

Effects of Dextrose on Knee Osteoarthritis

Phase 4

Conditions: Physical Activity
Functional Disturbance

Interventions: Drug: dextrose
Device: hyaluronic acid

First Posted Date: 2017-08-03

Last Posted Date: 2017-08-03

Lead Sponsor: Taipei Medical University

Target Recruit Count: 106

Registration Number: NCT03238183

Locations: 🇨🇳
Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan

Multiple Ascending Dose Study of MK-5160 in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-5160-002)

Phase 1

Completed

Conditions: Type 1 Diabetes Mellitus
Type 2 Diabetes Mellitus

Interventions: Biological: MK-5160 16 nmol/kg
Biological: Glargine 0.4 U/kg
Biological: MK-5160 32 nmol/kg
Biological: MK-5160 64 nmol/kg
Biological: Placebo to Glargine
Biological: Placebo to MK-5160
Drug: Dextrose
Biological: Glargine 0.6 U/kg